Hormone Resistant Prostate Cancer Completed Phase 2 Trials for Tasquinimod (DB05861)

Also known as: Hormone-Resistant Prostate Cancer

IndicationStatusPhase
DBCOND0038482 (Hormone Resistant Prostate Cancer)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02159950Sipuleucel-T With or Without Tasquinimod in Treating Patients With Metastatic Hormone-Resistant Prostate CancerTreatment